ES2429406T3 - Cannabinoides para su uso en el tratamiento del dolor neuropático - Google Patents

Cannabinoides para su uso en el tratamiento del dolor neuropático Download PDF

Info

Publication number
ES2429406T3
ES2429406T3 ES07733311T ES07733311T ES2429406T3 ES 2429406 T3 ES2429406 T3 ES 2429406T3 ES 07733311 T ES07733311 T ES 07733311T ES 07733311 T ES07733311 T ES 07733311T ES 2429406 T3 ES2429406 T3 ES 2429406T3
Authority
ES
Spain
Prior art keywords
thc
cbd
embc
pain
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07733311T
Other languages
English (en)
Spanish (es)
Inventor
Geoffrey Guy
Barbara Costa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Operations UK Ltd
Original Assignee
GW Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Pharma Ltd filed Critical GW Pharma Ltd
Application granted granted Critical
Publication of ES2429406T3 publication Critical patent/ES2429406T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES07733311T 2006-06-23 2007-06-21 Cannabinoides para su uso en el tratamiento del dolor neuropático Active ES2429406T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0612512A GB2439393B (en) 2006-06-23 2006-06-23 Cannabinoids for use in the treatment of neuropathic pain
GB0612512 2006-06-23
PCT/GB2007/002315 WO2007148094A1 (en) 2006-06-23 2007-06-21 Cannabinoids for use in the treatment of neuropathic pain

Publications (1)

Publication Number Publication Date
ES2429406T3 true ES2429406T3 (es) 2013-11-14

Family

ID=36803806

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07733311T Active ES2429406T3 (es) 2006-06-23 2007-06-21 Cannabinoides para su uso en el tratamiento del dolor neuropático

Country Status (8)

Country Link
US (3) US20100016418A1 (enExample)
EP (1) EP2037902B1 (enExample)
JP (2) JP5399898B2 (enExample)
CA (1) CA2656698C (enExample)
ES (1) ES2429406T3 (enExample)
GB (1) GB2439393B (enExample)
PL (1) PL2037902T3 (enExample)
WO (1) WO2007148094A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2450753B (en) * 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
DK2176208T3 (en) 2007-07-30 2015-04-27 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
GB2471523A (en) * 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
US8445034B1 (en) 2010-11-02 2013-05-21 Albert L Coles, Jr. Systems and methods for producing organic cannabis tincture
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2491118B (en) * 2011-05-20 2015-12-30 Otsuka Pharma Co Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US20150313868A1 (en) 2012-12-18 2015-11-05 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
US10774288B2 (en) 2013-09-18 2020-09-15 The Werc Shop, LLC Terpene-based compositions, processes, methodologies for creation and products thereby
GB2524469A (en) 2014-02-14 2015-09-30 Kind Consumer Ltd A cannabinoid inhaler and composition therefor
US9918961B2 (en) 2014-02-19 2018-03-20 Kind Consumer Limited Cannabinoid inhaler and composition therefor
EP3134393B1 (en) * 2014-04-21 2020-12-09 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Cyclohexenyl compounds, compositions comprising them and uses thereof
EP3160445B1 (en) 2014-06-26 2021-10-20 Island Breeze Systems Ca, LLC Mdi related products and methods of use
US9844518B2 (en) 2014-09-30 2017-12-19 MJAR Holdings, LLC Methods of growing cannabaceae plants using artificial lighting
WO2016092539A1 (en) * 2014-12-07 2016-06-16 One World Cannabis Ltd Use of cannabis to treat migraine
US10406186B2 (en) * 2015-01-31 2019-09-10 Constance Therapeutics, Inc. Cannabis oil extracts and compositions
US20160298151A1 (en) 2015-04-09 2016-10-13 Sher Ali Butt Novel Method for the cheap, efficient, and effective production of pharmaceutical and therapeutic api's intermediates, and final products
EP3302033A4 (en) 2015-05-28 2018-10-31 Tweed Inc. Cannabis plants having modified expression of thca synthase
MX385238B (es) 2015-11-24 2025-03-14 Constance Therapeutics Inc Composiciones de aceite de cannabis y metodos para preparacion de las mismas.
JP7054691B2 (ja) 2016-05-04 2022-04-14 インメド ファーマシューティカルズ インコーポレイティド 表皮水疱症及び関連する結合組織疾患の治療におけるカンナビノイドの局所製剤の使用
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
CA3010636A1 (en) 2016-06-29 2018-01-04 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
CN111372907A (zh) * 2017-09-01 2020-07-03 普优峰全球股份有限公司 合成大麻二酚组合物和用于制备其的方法
SG11202002169TA (en) * 2017-09-15 2020-04-29 Zelda Therapeutics Operations Pty Ltd Composition and method for treating autism
US12357604B2 (en) 2017-09-22 2025-07-15 Inmed Pharmaceuticals Inc. Topical formulations of cannabinoids and use thereof in the treatment of pain
US20190183849A1 (en) * 2017-10-21 2019-06-20 Alexander Kariman Compound and method for treatment of diseases and disorders
US20200315933A1 (en) * 2017-12-20 2020-10-08 Hanyi Bio-Technology Company Ltd. Use of cannabidiol or cannabis extract in preparation of skin whitening products
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
GB201806953D0 (en) * 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
SI25373A (sl) * 2018-05-08 2018-08-31 Danijela Marković Naravna orodisperzibilna tableta
JP2021527132A (ja) * 2018-06-15 2021-10-11 キャンパル アニマル セラピューティクス リミテッド カンナビノイド組成物及びそれを使用した治療法
US12144795B2 (en) 2018-09-05 2024-11-19 Purisys Llc Cannabidiol compositions having modified cannabinoid profiles
EP3864000A4 (en) 2018-10-10 2022-08-10 Treehouse Biosciences, Inc. CANNABIGEROL SYNTHESIS
WO2020220092A1 (en) * 2019-05-01 2020-11-05 Cannadol Pharmaceuticals Compositions and methods for pain and anxiety relief
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
JP2022551730A (ja) 2019-10-14 2022-12-13 パイク セラピューティクス，インコーポレイテッド カンナビジオールの経皮送達
BR112022008357A2 (pt) * 2019-11-07 2022-07-26 Amyris Inc Composições e métodos para a distribuição de canabinoides à pele
WO2022006187A1 (en) * 2020-06-30 2022-01-06 Np Pharma Holdings, Llc Methods of using cannabinoid compositions for inducing and promoting sleep
US11478446B2 (en) 2020-08-28 2022-10-25 Teresa Ann HANLON Pain relieving formulations containing cannabis and methods of making same
WO2022159507A1 (en) * 2021-01-19 2022-07-28 Merit Therapeutics, Inc. Combination of cannabinoids with additional therapeutic agents for treating diseases or disorders
JP2026520635A (ja) * 2023-06-09 2026-06-23 スケジュール １ セラピューティクス， インコーポレイテッド 片麻痺性片頭痛を治療するための組成物および方法
WO2026033228A1 (en) * 2024-08-08 2026-02-12 Curaleaf International Limited Formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949582B1 (en) * 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
DK1361864T3 (en) * 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
GB2381450B (en) * 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
EP1542657B8 (en) * 2002-08-14 2012-03-14 GW Pharma Limited Cannabinoid liquid formulations for mucosal amdinistration
GB2391865B (en) * 2002-08-14 2005-06-01 Gw Pharma Ltd Improvements in the extraction of pharmaceutically active components from plant materials
GB2394894B (en) * 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain

Also Published As

Publication number Publication date
US20120245224A1 (en) 2012-09-27
JP2009541479A (ja) 2009-11-26
US20190224140A1 (en) 2019-07-25
EP2037902A1 (en) 2009-03-25
CA2656698C (en) 2015-10-13
US20100016418A1 (en) 2010-01-21
GB2439393B (en) 2011-05-11
PL2037902T3 (pl) 2013-12-31
WO2007148094A1 (en) 2007-12-27
GB0612512D0 (en) 2006-08-02
GB2439393A (en) 2007-12-27
EP2037902B1 (en) 2013-07-03
JP5399898B2 (ja) 2014-01-29
JP2013241471A (ja) 2013-12-05
CA2656698A1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
EP2037902B1 (en) Cannabinoids for use in the treatment of neuropathic pain
JP6147249B2 (ja) 神経因性疼痛の治療において使用するためのカンナビノイド
US10660872B2 (en) Methods for treatment of cognitive decline
Rahmati et al. Anti-epileptogenic and antioxidant effect of Lavandula officinalis aerial part extract against pentylenetetrazol-induced kindling in male mice
Hayman et al. Capsaicin: A review of its pharmacology and clinical applications
US20100035978A1 (en) Combination of cannabinoids for the treatment of peripheral neuropathic pain
ZA200610242B (en) Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis
Melo et al. (−)-α-Bisabolol reduces orofacial nociceptive behavior in rodents
RU2701720C1 (ru) Комбинации пальмитоилэтаноламида для лечения хронической боли
CA3000918A1 (en) Pharmaceutical compositions containing cannabis, uses thereof and methods for improving sleep quality
ES2886534T3 (es) Una composición para el tratamiento de la neuropatía, un procedimiento y un método de tratamiento de la misma
Chan et al. Treatments used in complementary and alternative medicine
Blebea et al. EVALUATION OF THERAPEUTIC POTENTIAL OF CANNABIDIOLBASED PRODUCTS IN ANIMAL MODELS OF EPILEPTIC SEIZURES, NEUROPATHIC PAIN AND CHRONIC INFLAMMATION.
PT2424523E (pt) Formulação de spray sublingual compreendendo dihidroartemesinina
RU2406521C2 (ru) Применение лавандового масла для профилактики и лечения неврастении, соматоформного расстройства и других болезней, связанных со стрессом
US11395813B1 (en) Cannabinoids based pharmaceutical composition
US12357587B2 (en) Cannabinoid monoterpene based pharmaceutical topical composition for musculoskeletal pain
Jain Study of herbal drugs for the treatment of sexual dysfunction
US20260108537A1 (en) Integrative Treatment for Shingles Based on Cannabinoid Compounds
Nouri et al. Gabaergic system role in aqueous extract of Valeriana officinalis L. root on PTZ-induced clonic seizure threshold in mice
Garcia-Carvajal et al. Uses in Pharmaceutical Industry
Gupta et al. Review on Impact of natural plant products on computer vision syndrome
WO2014184398A1 (es) Formula farmacéutica para el tratamiento de afecciones que involucran al sistema venoso y linfático, al sobrepeso y la obesidad
Bedard Kava: the root to happiness?
ES1077318U (es) Contenedor plegable y apilable para residuo de lámparas